Yinhua CSI Innovative Drugs Industry ETF (159992) Rises 0.93% in Early Trading; Institutions: Biomedical Industry Fundamentals Expected to Accelerate Improvement

NewTimeSpace News - As of 10:45 on April 2, 2026, the Yinhua Innovative Medicine ETF (159992) rose 0.93%, with its latest price reaching 0.87 yuan. Looking at a longer timeframe, as of April 1, 2026, the ETF has accumulated a gain of 10.36% over the past week. (The stocks listed above are solely index constituents and do not constitute specific investment recommendations.)

In terms of liquidity, the Yinhua Innovative Medicine ETF recorded an intraday turnover rate of 3.69% and a trading volume of 574 million yuan. Looking at a longer timeframe, as of April 1, the ETF's average daily trading volume reached 872 million yuan over the past week, ranking first among comparable funds.

Regarding fund size, the Yinhua Innovative Medicine ETF's latest AUM stands at 15.549 billion yuan, hitting a new high for the past month and ranking 1st among 7 comparable funds. (Data source: Wind)

In terms of fund shares, the Yinhua Innovative Medicine ETF increased by 3.112 billion shares over the past 3 months, achieving substantial growth and ranking 1st among 7 comparable funds in terms of new share additions. (Data source: Wind)

For capital flows, the Yinhua Innovative Medicine ETF recorded a net outflow of 400 million yuan in the latest session. Looking at a longer timeframe, over the past 23 trading days, 12 days saw net inflows, with a total of 56.8228 million yuan attracted, representing an average daily net inflow of 2.4706 million yuan. (Data source: Wind)

Data indicates continued positioning by leveraged funds. The Yinhua Innovative Medicine ETF recorded a margin purchase of 72.774 million yuan in the latest session, with its latest margin balance reaching 525 million yuan. (Data source: Wind)

As of April 1, the Yinhua Innovative Medicine ETF has gained 21.47% over the past 2 years. In terms of return capability, as of April 1, 2026, since its inception, the ETF has achieved a maximum monthly return of 22.79%, a maximum consecutive rising period of 4 months, a maximum consecutive gain of 53.27%, and an average monthly return of 6.61% during rising months. As of April 1, 2026, the Yinhua Innovative Medicine ETF has outperformed its benchmark by 0.55% in annualized returns over the past 2 years.

Regarding drawdown, as of April 1, 2026, the Yinhua Innovative Medicine ETF's relative benchmark drawdown this year was 0.15%.

In terms of fee structure, the Yinhua Innovative Medicine ETF charges a management fee of 0.50% and a custody fee of 0.05%.

For tracking accuracy, as of April 1, 2026, the Yinhua Innovative Medicine ETF's tracking error over the past 5 years was 0.037%.

From a valuation perspective, the CSI Innovative Medicine Industry Index tracked by the ETF currently has a price-to-earnings ratio (PE-TTM) of only 44.18x, standing at the 6.87th percentile over the past year, meaning the valuation is lower than 93.13% of the time during the past year, indicating a historically low level.

The Yinhua Innovative Medicine ETF closely tracks the CSI Innovative Medicine Industry Index, which selects up to 50 most representative listed companies from among those whose main business involves innovative drug research and development as index constituents to reflect the overall performance of innovative medicine industry listed companies.

CMB International noted that the biomedical industry's upgraded positioning as an emerging pillar industry indicates that full-chain policy dividends will continue to be released. Breakthroughs in AI pharmaceutical technology and the explosive growth of Chinese innovative drug overseas BD form dual resonance, and industry fundamentals are expected to accelerate improvement. Currently, domestic innovative drug overseas cooperation has upgraded from single pipeline licensing to platform-level cooperation, with multinational pharmaceutical companies' recognition of China's pharmaceutical R&D capabilities systematically improving.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.